



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com
CIN. : L74899DL1978PLC009181



January 21, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Press Release for Unaudited Financial Results for quarter and nine months ended December 31, 2025

Dear Sir/ Madam,

In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release along with Investor's presentation for the Unaudited Financial results for the quarter and nine months ended December 31, 2025.

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal

Company Secretary & Compliance Officer



Jagsonpal Pharmaceuticals Ltd. announces Q3 & 9MFY26 Results

9MFY26 PAT up 12.5%, Cash balance of ₹ 1,757 Mn

Gurugram, January 21st, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial results for the quarter ended December 31, 2025.

Rs. in Mn	Q3FY26	Q3FY25	YoY %	9MFY26	9MFY25	YoY%
Revenue	729	740	-1%	2,230	2,102	6%
Operating EBITDA*	166	171	-3%	503	482	5%
EBITDA Margin*	22.7%	23.1%	-0.4 bps	22.6%	22.9%	-35 bps
ESOP Cost	3	13	-78%	34	58	-41%
PAT**	125	115	10%	359	319	13%

*Operating EBITDA and EBITDA margins before ESOP cost

**Excluding exceptional items

Q3& 9MFY26 Key Highlights:

- Consistent revenue trajectory:** Q3 revenue stood at ₹ 729 Mn, while 9M delivered a 6% YoY growth to ₹ 2,230 Mn.
- Operational discipline sustains EBITDA Margins:** Op. EBITDA of ₹ 166 Mn in Q3; Margin at 22.7%; while 9M delivered an uptick of 5% YoY to ₹ 503 Mn - demonstrating efficient cost management and operating resilience.
- Profitability strengthens on robust execution:** Net Profit rose to ₹ 125 Mn in Q3 with margins expanding by 160 bps YoY to 17.1% while 9M PAT grew 12.5% YoY to ₹ 359 Mn underscoring sustained profitability momentum.
- Robust free cash generation:** Cash balance at ₹ 1,757 Mn as of Dec 31, 2025 - an uptick of ₹ 152 Mn underscoring strong brand equity and operational excellence.

Commenting on the performance, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said,

"We have reported stable performance during the nine months of FY26, even as we took focused initiatives to support growth. These should start reflecting in our performance from the ongoing quarter. Revenue increased 6% YoY to ₹2,230 Mn, while EBITDA (pre-ESOP) grew 5% YoY to ₹503 Mn. Operational PAT rose 12.5% YoY to ₹359 Mn, with Operating PAT margins expanding by 95 bps to 16.1%, underscoring the strength of our brands and our business model.

On a quarterly basis, performance was largely flat, with revenue at ₹729 Mn, EBITDA (pre-ESOP) of ₹166 Mn, with Operational PAT increasing 10% to ₹125 Mn. Based on initial estimations, we have provided for an additional past service cost of ₹ 21 Mn.



*The company continues to maintain a strong liquidity position, with **cash balances increasing by ₹152 Mn during the quarter to ₹1,757 Mn**. This robust balance sheet, supported by strong fundamentals and a resilient brand portfolio, provides a solid foundation and the company is confident of stronger growth going forward, starting from Q4 of the current fiscal."*

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
<p>Email: cs@jagsonpal.com, Tel: +91 124 4406710</p> <p>Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181</p> <p>Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi – 110020</p> <p>Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015</p>	<p>Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750</p>



Jagsonpal Pharmaceuticals Limited

**Q3 & 9MFY26
Investor
Presentation**

21st January 2026



Safe Harbor

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and several risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) change in the general market and macro-economic conditions, 2) governmental and regulatory trends, 3) successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 4) movements in currency exchange and interest rates, 5) increase in the competitive pressures and technological developments, 6) changes in the financial conditions of third parties dealing with us, 7) changes in laws and regulations that apply to our customers, suppliers and the pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Jagsonpal Pharmaceuticals Limited may vary materially from those described in the relevant forward-looking statements.

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation because of new information, future events or otherwise.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.



Management Commentary



We have reported stable performance during the nine months of FY26, even as we took focused initiatives to support growth. These should start reflecting in our performance from the ongoing quarter. Revenue increased 6% YoY to ₹2,230 Mn, while EBITDA (pre-ESOP) grew 5% YoY to ₹503 Mn. Operational PAT rose 12.5% YoY to ₹359 Mn, with Operating PAT margins expanding by 95 bps to 16.1%, underscoring the strength of our brands and our business model.

On a quarterly basis, performance was largely flat, with revenue at ₹729 Mn, EBITDA (pre-ESOP) of ₹166 Mn, with Operational PAT increasing 10% to ₹125 Mn. Based on initial estimations, we have provided for an additional past service cost of ₹ 21 Mn.

The company continues to maintain a strong liquidity position, with cash balances increasing by ₹152 Mn during the quarter to ₹1,757 Mn. This robust balance sheet, supported by strong fundamentals and a resilient brand portfolio, provides a solid foundation and the company is confident of stronger growth going forward, starting from Q4 of the current fiscal.

Manish Gupta
Managing Director

**High
Governance
Standards**

**Innovation
Backed Portfolio
Expansion**


**Financial
Strength fuels
Strategic Agility**

Q3 & 9MFY26 Highlights



Highlights - Stable operations, Strong Balance Sheet

9MFY26 PAT up 12.5%, Cash balance up ₹ 152 Mn in Q3FY26




Consistent revenue trajectory

Q3 revenue stood at ₹ 729 Mn, while 9M delivered a 6% YoY growth to ₹ 2,230 Mn.



Operational discipline sustains EBITDA Margins

Op. EBITDA of ₹ 166 Mn in Q3; Margin at 22.7%; while 9M delivered an uptick of 5% YoY to ₹ 503 Mn - demonstrating efficient cost management and operating resilience.



Profitability strengthens on robust execution

Net Profit rose to ₹ 125 Mn in Q3 with margins expanding by 160 bps YoY to 17.1% while 9M PAT grew 12.5% YoY to ₹ 359 Mn underscoring sustained profitability momentum.




Robust free cash generation

Cash balance at ₹ 1,757 Mn as of Dec 31, 2025 - an uptick of ₹ 152 Mn underscoring strong brand equity and operational excellence.


Financial Highlights: 9MFY26




Revenue from Operations




Gross Profit & Margin (%)



EBITDA & Margin* (%)



PAT & Margin* (%)




(All values in ₹ Mn)

* EBITDA and EBITDA margin is calculated Pre-ESOP | PAT and PAT margin excludes impact of exceptional item


Financial Highlights: Q3FY26




Revenue from Operations




Gross Profit & Margin (%)



EBITDA & Margin* (%)



PAT & Margin* (%)



Income Statement

(All values in ₹ Mn)



Particulars	Q3FY26	Q3FY25	% Change	9MFY26	9MFY25	% Change
Revenue from Operations	729	740	- 1%	2,230	2,102	6%
Total Expenses	564	569	- 1%	1,727	1,620	7%
EBITDA*	166	171	- 3%	503	482	5%
EBITDA Margin*	22.7%	23.1%	- 41 bps	22.6%	22.9%	- 35 bps
Other Income	30	23	28%	88	54	63%
ESOP Cost	3	13	- 78%	34	58	- 41%
Depreciation	24	24	- 1%	71	58	22%
EBIT	169	157	7%	486	419	16%
EBIT Margin	23.1%	21.3%	184 bps	21.8%	19.9%	187 bps
Finance Cost	3	3	- 1%	8	7	11%
PBT	166	155	7%	478	412	16%
PBT Margin	22.8%	20.9%	183 bps	21.5%	19.6%	188 bps
Tax (Business profits)	41	40	-	120	93	29%
Operating PAT	125	115	10%	359	319	13%
Operating PAT %	17.1%	15.5%	160 bps	16.1%	15.2%	95 bps
Exceptional Items (net of taxes)**	- 16	205	-	- 16	168	-
Net PAT	110	320	-	343	488	-

- EBITDA and EBITDA margin is calculated Pre-ESOP

** Exceptional item: Q3FY26 - Provisioning for New labour code impact, Q3FY25 - Sale of Faridabad facility





Key Balance Sheet Items

(All values in ₹ Mn)



Particulars	31-Dec-25	30-Sep-25	31-Dec-24
Shareholders Funds	2,657	2,528	2,319
Tangible Assets	6	6	8
Intangibles	798	818	875
Right of Use Assets	72	76	86
Financial Assets (Cash & Equivalents)	1,757	1,604	1,321
Other Non-Current Assets (Net)	32	51	23
Lease liabilities	85	88	96
Net Working Capital	126	116	146

5-Year journey in a nutshell



The Three-Pronged Growth Strategy



New Product Launch

- Niche, Innovation driven
- Launch 4-6 products annually, driving market engagement and revenue

Volume Growth

- Sales Force Empowerment
- Targeted training boosts medical rep knowledge and productivity

Price Increases

- Non-NLEM Portfolio
- Competitive Pricing with Quality



About the Company

Jagsonpal - Legacy of 'Quality and Trust' since 1964



100% India Centric Business

PAN India presence; Sub-chronic Presence

Deep Market Penetration

Presence across 4000+ towns and cities through 1200+ distributors, enabling wide accessibility and consistent brand recall.

Quality culture imbibed across Operations

CMOs fully complaint with WHO-GMP and ISO 9001:2015 standards with over 300+ quality checks

Enduring Doctor Confidence

Trusted by >50,000 doctors nationwide - a legacy of prescription confidence built over decades

Therapy powerhouse with deep domain expertise

Spanning branded generics, trade generics & OTC; Ranked #8 in CVM

Power Brand portfolio boosting market share

Top 10 contributing 63% of sales; includes 5 #1 ranked molecules and 14 brands in the top 5

Inorganic growth capabilities, supported by strong balance sheet

Demonstrated strategic acquisition with disciplined integration, driving profitability and margins

Lean Operations: Asset Light Model

Outsourced R&D and Manufacturing; built for growth without capital strain

Backed by promoter conviction, long term vision

Strategic alignment towards long term value creation

Strong Presence in Key Therapies



Gynecology

- 7th as per CMARC RPM in CVM
- Reaching ~90% of the Gynecologists nationwide, engagement with 35,000 out of 39,000 gynaecs.
- Leaders in Progesterone therapeutic segment

Pediatrics

- 17th as per CMARC RPM in CVM
- Maintaining regular connect with 9,700 out of 35,650 Pediatricians, ensuring ~27% coverage.
- Key segments include Gut Health (Probiotic), Cough, Cold & Fever, Anti- itch, Diarrhea and Dysentery

Ranked 8th in
Corporate CVM
(as per CMARC
RPM)

Orthopedics

- 2nd as per CMARC RPM in CVM
- Reaching ~80% of the Orthopedists through consistent engagement with 10,000 out of 13,000.
- Strong presence in Osteoporosis and Osteoarthritis segment

Dermatology

- 30th as per CMARC RPM in CVM
- Operates in Demelanizing, Antifungals and Anti-histamines segments
- Regular connect with ~4,500 out of 11,500 Dermatologists in India, ensuring ~40% coverage.

Building A High-impact Asset Light Model



Capital Intensive Activities - Out-Sourced

1

Ideation



In-house Ideation For Innovative Drug Concepts.
1-2 New Product Launches Every Quarter

Focus On Mid-Sized, Sub Chronic Segment

Aim For Substantial Market Share In Niche Segment

2

Research & Development



Partner with leading CDMO players for product research and development

3

Contract Manufacturing



Partner with leading Indian CMO for manufacturing

4

PAN-India Distribution



1000+ Medical Reps for brand promotion

18 stocking points across the country to ensure last-mile delivery



Strategic Pillars



**Innovation - Niche
Molecules,
Dominant Market
Share**

**Large, well
trained
Work Force
of 1000+
Medical
Reps**

**Lean
Operations:
Asset Light
Model**

**Inorganic Growth
Powered by
Strategic
Acquisition**

Niche Dominators: Our Top 10 Products



Key Products	Indocap, Indocap SR	Maintaine Tabs	Metadec	Maintaine Injections	Endoreg
Indication	Sustained Pain Relief, Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis	Threatened & Habitual Abortion, Preterm Delivery	Osteoporosis, Fracture Healing	Threatened & Habitual Abortion, Preterm Delivery, Luteal Phase Support during ART	Endometriosis, Endometriosis associated Pelvic Pain (EAPP)
IPM Rank	1st	1st	2nd	2nd	4th
Company Market Share (%)	63%	40%	21%	17%	9%
Molecule Market Size (Mn)	562	232	1,533	1,393	1,000

Niche Dominators: Our Top 10 Products




Key Products	Lycored SG	Lycored Syrup	Doxypal DR-L	Eukroma Cream	Tinilox MPS
Indication	Antioxidant for safer pregnancy.	Enhances day-to-day immunity	Helps in the treatment of bacterial infections.	Helps in the treatment of Melasma.	Treatment of Diarrhea and Dysentery.
IPM Rank	3 rd	1 st	3 rd	1 st	1 st
Company Market Share (%)	12%	65%	12%	32%	72%
Molecule Market Size (Mn)	773	147	852	165	67

(Source: Pharmarack)


Execution Excellence across all parameters







Cash Rich and Growth Ready



Capital Optimized for scalable growth



Rewarding shareholders; Enhanced Payouts



*Net of ₹ 928 Mn spent on acquisition in FY25



MySakhi Initiative

Where Business Meets Social Impact



Shaping the Future

Expanding outreach with self-testing kits, discounted lab tests, and an online forum to support women's holistic well-being.

Driving Menopause Awareness

Deliver impactful virtual sessions on menopause, supported by social media campaigns and community engagement.

Empowering Women Through MySakhi.in

A dedicated website offering educational resources, health tools, and community support focused on women's health

Transforming Hygiene Access

Built modern sanitation complexes across Punjab, Haryana, and Uttarakhand, fostering health and dignity for schoolgirls

Real World Impact: Beyond The Bottom Line

14 pink toilets built in Haryana, Punjab, Uttarakhand & Delhi NCR Regions

Ongoing webinars, spearheaded by specialist doctors focused on Menopause awareness

Collaborating with NGOs for hygiene awareness and infrastructure development

Ongoing CSR Initiatives



Empowering girls through hygiene and education - 14 toilets built across North India, with sanitary support and NGO-led awareness driving dignity and inclusion.



Thank You

Feel free to reach out to us if you have any questions

JAGSONPAL PHARMACEUTICALS LTD.

Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi - 110020



cs@jagsonpal.com



www.jagsonpal.com



+91 124 4406710

INVESTOR RELATIONS

Soumya Chhajed

Email: soumya@goidiaadvisors.com

Ph: +91 8619707750

